Similar to the Swedish guidelines, the Danish Breast Cancer Cooperative Group recommends Ki67 to be scored in hot spots, but also in the invasive tumor fronts and in 5–10% intervals [45]. This evidence concerns the gene MKI67 and breast carcinoma.